Member Info for Fevertreeman

Given the Co has so far hit all the milestones - some show of faith from Barrington is called for here. No good just sitting on nil cost options and pretending you are investing. Next milestone will be the determination around Medicare reimbursement, which looks like a Q4 announcement and should help snap the share back to life.

Agree that AIM is friendless, and not doing the job it was originally designed for, and successive governments have failed to provide the fiscal incentives for institutions to invest including the ludicrous tax that is stamp duty among other things. And REnx is also a factor, but self-help and self-belief are powerful signals in these types of emerging tech businesses and frankly I dont see enough support from the Board or management.

1. Renx is an issue BUT if Barrington wants to walk the wk rather than just do upbeat investor videos from Tennessee, then

Whilst the company at the time was in ddep deep trouble, it seem amazing that Ashmore received a cash bonus equivalent to 5.5x his salary.............shareholders have been absolutely hammered but not it seems management who are being rewarded handsomely for delivering zero!

As I have pointed out before, checking Ashmore's remuneration in the AnnualReport is worthwhile.

Although no bonus was paid in FY23 because, surprise, surprise the threshold Adjusted EBITA was not met, Ashmore & Quested were granted huge one-off cash-based awards under the Existing Schemes Award Plan (ESA Plan) back in Feb 2021 which vested start of 2023. The plan triggered on the basis that there was average 6mthy liquidity of at least £20m cash (look at Note 2 Page 66 to see how widely that liquidity)> and ker-boom you sell off some parts of the business and if you're Ashmore's you get a cash (yes cash, not shares) payment of £2.2m and Quested £1.7m.

Shareholders have seen negative returns from this shower...Amusingly Ashmore & Quested are/were participants in a Value Creation Plan (VCP)....so thats going well isn't it!!!

Given the slide since the fund raise, and Barrington's positivity am genuinely surprised that no one on the board has bought any stock. All very sitting on loads of share options granted for free but there comes a time when investors want to see maangemetn actually committing their own cash. Barrington shoyld take note

Exactly correct. The only management change at Board level is that Quested the CFO left as of end August....having flagged his intention to step down

You made me laugh - Pinocchio Adams banging on about security issued when there is nothing to bloody protect apart from some trenchs & a few prefab buildings

I dont know what webinar you were listening to, but I heard the same one and came away with absolutely nothing new. Newland was in full stock promoter mode...spouting his usual Del Boy "T/morrow we'll be millionaires Rodney" lines. Underwhelming format with basic-level questions; not a single question that put Newland & Griffiths on the spot. Only thing that raised a pulse was answer to US listing. Griffiths explained the Co already has an ADR listing and that its 2 biggest s/holders were American. Agreed that the US remains under consideration but that " you have to get the timing right", and that it was an expensive exercise and track record of others who listed too early wasn't great. The issue of course that Newland & Griffiths has is that thanks to Newland's incessant inability to deliver on his own objectives; the failure to meet commercial or financial targets and ; the silence & amnesia that follows supposedly breakthough announcements (Solaris being one), an American listing is just not going to change things. In effect this is what GFriffths was admitting. Until Newland & Griffiths can actually deliver against their own forecasts the enormous Trust deficit will remain. The next staging post is the Interims this Sept. If the Co delivers decent figs and confirms FY forecasts that they only confirmed 6 weeks ago, then maybe investor confidence will slowly start to return. However the omens dont look promising.

They've already appointed an interim CFO. Check their RNS feed

Does finally seem that the tap is being turned on for rail upgrades. Add to that QRO continuing to preform...Petards is starting to slowly recover...the Abdullahs have been very poor stewards of the business in recent years. let's hope that Affini marks a much need turning point....share price has a long recovery road ahead of it...

For all Ashmore's bullishness about progress at HSS, the share price has barely moved for months, so Ashmore has it all to do with the Sept 1h results due out this month. Currently, Mr Market either (1) has no interest in HSS or (2) isn't convinced that Ashmore's digital strategy will drive sustainable revenue * eps growth to justify rerating (this view not helped by Ashmore' sale of revenue-generating operations + resignation of CFO + loss of big AMEY contract)

Must be divisional CEO. Change of Group CEO would require statement to stock exchange, so ashmore still in the hot seat.....

Given how many 'gurus' are attending, what guru is Adams?

Newland conducts his investor relations with all the duty of care of a child left alone in a sweet shop. To blatantly and repeatedly make statements that Board is comfortable with FY forecasts of c£6m (in order to pump the the placing) without providing any solid fact-based evidence to support the claim either means (1) he has good reason to believe that £5m worth of revenue will arrive in next 16 weeks displaying a self-belief bordering on the messianic or (2) it reveals a cynical disregard for the actualite, instead replaced with "I'll make it up as I go along because I can find excuses etc..."

If Newland & Griffiths issue a revenue warning after raising funds at 15p in June & assuring investors that the company stood by the £6.4m est for 2024, then I won't be the only one demanding that the Chairman act.

Am looking forward to putting Newland on the spot on the 6pm Shares webinar on Sept 3rd. Suggest all of us sign up to see whether Nero & his shifty sidekick can actually answer some pertinent questions

AS GGecko pointed out Newland has consistently hyped, blustered, misdirected, deflected & obfuscated about pretty much everything: timelines, revenue projections, commercial deals, clinical trials, number of partners etc.....

- Latest example: June 5th Placing RNS announcement (my observation in brackets):

- "The Company has a strong current pipeline of opportunities that has more than doubled year to date (Doubled Year -to-date: from 1 to 2 is doubling! This means nothing without a definitive fig that he won't provide) , with significant potential growth opportunities (significant potential....i.e nothing concrete now) across a variety of end customers (i.e. tiny players), including large pharma. As such, the management remains confident in delivering strong growth in 2024 in line with current market expectations."

Other examples:

- April 21st 2023 Prelims RHS Announcement:

· Prostate cancer - partnership established with Solaris Health, a major United States urology group to evaluate the Parsortix system in prostate cancer. Clinical study now underway and expected to complete during 2023 (AUGUST 2024: Where's the update Newland? !!!!)

- April 19 2023 BioView Deal to develop a CTC-based HER2 assay - First phase expected to generate c. £1.2 million revenue...estimated to take around a year to complete with the assay development work generating c. £1.2 million of revenues for ANGLE." (16 months on from this RNS Nero has given us no update!!!)

Jan 2023: Business Update:

Studies are expected to complete in 2023 with a view to Solaris marketing a Parsortix prostate cancer test to its patient base of over 729,000 unique patients annually. (August 2024 Where's the update Newland???????)

Pinocchio Adams limbering up for another cash call!

You clearly misunderstand how listed companies actually operate and how they are supposed to manage their relationships with shareholders.

Https://www.petards.com/contract-win-23rd-august-2024/